| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2e3830f35387a1c32061dea3ee310851 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-24 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56972
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-436
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569 |
| filingDate |
2018-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d9c3c0cb33b0696c80d228ab49e0bf42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b07dbd7616a48e80aad494797fe06e76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7bb4d8962d6743351e1f1bc1a6238d48 |
| publicationDate |
2019-05-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2019084495-A1 |
| titleOfInvention |
IDENTIFICATION OF EPIGENETIC AND TRANSCRIPTIONAL TARGETS TO PREVENT AND REVERSE T-LYMPHOCYTE EXHAUST |
| abstract |
The present invention provides methods for preventing, reversing or increasing T-cell depletion in a patient having a disease. The present invention also provides methods of treating a disease in a patient having the disease.nThe present invention further relates to a genetically modified T cell comprising a targeted high priority epigenetic pathway, and uses thereof. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-116478956-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-116083599-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-116478956-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110687285-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109055372-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114164277-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109055372-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021011493-A1 |
| priorityDate |
2017-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |